CD274 and non-small cell lung carcinoma: In TETs, it may be expected that high PD-L1 expression would lead to a better response to anti-PD-L1 treatment, such as in NSCLC; however, the limited clinical trials of anti-PD-L1 therapy in TETs (10, 11) have shown controversial results.